Dopamine D3 receptor ligands for the treatment of tobacco dependence

Expert Opinion on Investigational Drugs

Volumn 16, Issue 1, 2007, Pages 45-57

  Le Foll, Bernard ^a   Goldberg, Steven R ^b   Sokoloff, Pierre ^c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

BP 897; Buproprion; Conditioning dependence; Dopamine D'3; Nicotine; Relapse; Rimonabant; SB 277011A; Tobacco; Varenicline

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BP 897; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DIANICLINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; IMIPRAMINE; N [4 (1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL)BUTYL] 3 PHENYLACRYLAMIDE; N [4 (2 (6 CYANO 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL)ETHYL)CYCLOHEXYL] 4 QUINOLININECARBOXAMIDE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NICOTINE; NICOTINIC AGENT; NORTRIPTYLINE; QUINPIROLE; RIMONABANT; SR 14176; SSR 591813; ST 198; VARENICLINE; LIGAND;

AMYGDALOID NUCLEUS; BRAIN REGION; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; IN VIVO STUDY; MOTIVATION; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NUCLEUS ACCUMBENS; PROTEIN LOCALIZATION; REINFORCEMENT; RELAPSE; REVIEW; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME; ANIMAL; DRUG ANTAGONISM; HUMAN; METABOLISM; METHODOLOGY; SMOKING CESSATION;

ANIMALS; DOPAMINE ANTAGONISTS; HUMANS; LIGANDS; RECEPTORS, DOPAMINE D3; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 33845711416     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.1.45     Document Type: Review

References (116)

1. HENNINGFIELD JE, GOLDBERG SR: Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol. Biochem. Behav. (1983) 19(6):989-992.
2. STOLERMAN IP, SHOAIB M: The neurobiology of tobacco addiction. Trends Pharmacol. Sci. (1991) 12:467-473.
3. FIORE MC, BAILEY WC, COHEN SJ et al: Treating tobacco use and dependence. Clinical practice guideline. US Department of Health and Human Service. Public Health Service, Rockville, USA (2000).
4. WEST R, McNEILL A, RAW M: Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax (2000) 55(12):987-999.
5. LE FOLL B, MELIHAN-CHEININ P, ROSTOKER G: Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency. Eur. Psychiatry (2005) 20:431-441.
6. GONZALES D, RENNARD SI, NIDES M et al: Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, versus sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA (2006) 296(1):47-55.
7. NIDES M, ONCKEN C, GONZALES D et al: Smoking cessation with varenicline, a selective αβ2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch. Intern. Med. (2006) 166(15):1561-1568.
8. JORENBY DE, HAYS JT RIGOTTI NA et al.: Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, versus placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA (2006) 296(1):56-63.
9. PONTIERI FE, TANDA G, ORZI F, DI CHIARA G: Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature (1996) 382:255-257.
10. PONTIERI FE, TANDA G, DI CHIARA G: Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the shell as compared with the core of the rat nucleus accumbens. Proc. Natl. Acad. Sci. USA (1995) 92:12304-12308.
11. SOKOLOFF P, LERICHE L, LE FOLL B: Dopamine receptors: structure, function and implication in psychiatric disorders. In: Psychopharmacogenetics. Gorwood P, Hamon MD (Eds), Springer Science Business Media, Inc, New York, USA (2006):357-419.
12. BJÖRKLUND A, LINDVALL O: Dopamine-containing systems in the CNS. In: Handbook of chemical neuroanatomy. Björklund A, Hökfelt T (Eds), Elsevier, Amsterdam, Netherlands (1984):55-122.
13. WISE RA, ROMPRE PP: Brain dopamine and reward. Ann. Rev. Pychol. (1989) 40:191-225.
14. WISE RA: Dopamine, learning and motivation. Nat Rev. Neurosci. (2004) 5(6):483-494.
15. SALAMONE JD, CORREA M, MINGOTE SM, WEBER SM: Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr. Opin. PharmacoL (2005) 5(1):34-41.
16. 11C) raclopride. Synapse (2004) 54(2):65-71.
17. CORRIGALL WA, COEN KM: Opiate antagonists reduce cocaine but not nicotine self-administration. Psycohopharmacology (Berl.) (1991) 104(2):167-170.
18. 1 dopamine receptor. Nature (1990) 347:72-76.
19. 1 receptor encoded by an intronless gene on chromosome 5. Nature (1990) 347:80-83.
20. 1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. (1991) 87:6723-6727.
21. 1 dopamine receptors. Nature (1990) 347:76-86.
22. 3) as a target for neuroleptics. Nature (1990) 347(6289):146-151.
23. 4 receptor with high affinity for the antipsychotic clozapine. Nature (1991) 350:610-614.
24. 1, Nature (1991) 350:614-619.
25. 3H]-hydroxy-N,N di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA (1992) 89(17):8155-8159.
26. 3 receptor in reactivity to cocaine-associated cues in mice. Eur.J. Neurosci. (2002) 15(12):2016-2026.
27. KOOB GF: Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. (1992) 13:177-184.
28. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J. Neurosci. (1996) 16(19):6100-6106.
29. 3 receptor expression accompanying behavioural sensitization to nicotine in rats. Synapse (2003) 47(3):176-183.
30. 3 receptor ligands. Molec. Psychiatry (2003) 8(2):225-230.
31. GUILLIN O, GRIFFON N, DIAZ J et al.: Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. Int. Rev. Neurobiol. (2004) 59:425-444.
32. KENNY PJ, FILE SE, RATTRAY M: Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Res. Mol. Brain Res. (2000) 85(1-2):234-238.
33. HELLSTROM-LINDAHL E, COURT J, KEVERNE J et al.: Nicotine reduces Aβ in the brain and cerebral vessels of APPsw mice. Eur J. Neurosci. (2004) 19(10):2703-2710.
34. 3 receptor expressions:implications for drug-conditioning. Neuroreport (2005) 16(2):175-178.
35. GRIMM JW, LU L, HAYASHI T et al: Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J. Neurosci. (2003) 23(3):742-747.
36. 3 receptor expression and triggers behavioural sensitization. Nature (2001) 411(6833):86-89.
37. HALL FS, DRGONOVA J, GOEB M, UHL GR: Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacology (2003) 28(8):1485-1490.
38. HORGER BA, LYASERE CA, BERHOW MT et al: Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J. Neurosci. (1999) 19(10):4110-4122.
39. LU L, DEMPSEY J, LIU SY, BOSSERT JM, SHAHAM Y. A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. J. Neurosci. (2004) 24(7):1604-1611.
40. GRIMM JW, HOPE BT, WISE RA, SHAHAM Y: Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature (2001) 412(6843):141-142.
41. COURT JA, LLOYD S, THOMAS N et al: Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience (1998) 87(1):63-78.
42. 3 receptor agonist. Nature (1999) 400(6742):371-375.
43. 3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. (2000) 294(3):1154-1165.
44. 3 receptor function. Nat. Med. (2003) 9(6):762-767.
45. 3 receptor and drug dependence: effect on reward or beyond? Neuropharmacology (2005) 49(4):525-541.
46. 3 receptors mediate the effects of BP897 on L-DOPA-induccd hyperactivity in monoamine-depleted rats. Exp. Neurol. (2006) 202(1):85-92.
47. MARKOU A, WEISS F, GOLD LH et al: Animal models of drug craving. Psychopharmacology (1993) 112:163-182.
48. EVERITT BJ, ROBBINS TW: Second-order schedules of drug reinforcement in rats and monkeys: measurement of reinforcing efficacy and drug-seeking behaviour. Psychopharmacology (Berl.) (2000) 153(1):17-30.
49. SCHINDLER CW, PANLILIO LV, GOLDBERG SR: Second-order schedules of drug self-administration in animals. Psychopharmacology (Berl.) (2002) 163(3-4):327-344.
50. DEROCHE-GAMONET V, BELIN D, PIAZZA PV: Evidence for addiction-like behavior in the rat. Science (2004) 305(5686):1014-1017.
51. VANDERSCHUREN LJ, EVERITT BJ: Drug seeking becomes compulsive after prolonged cocaine self-administration. Science (2004) 305(5686):1017-1019.
52. 1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. (2005) 312(3):875-883.
53. CORRIGALL WA, COEN KM: Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl.) (1989) 99(4):473-478.
54. CHANCE WT, MURFIN D, KRYNOCK GM, ROSECRANS JA: A description of the nicotine stimulus and tests of its generalization to amphetamine. Psychopharmacology (Berl.) (1977) 55(1):19-26.
55. STOLERMAN IP: Discriminative stimulus effects of nicotine in rats trained under different schedules of reinforcement. Psychopharmacology (Berl.) (1989) 97(1):131-138.
56. 3 ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology (2005) 30:720-730.
57. MALIN DH, LAKE JR, NEWLIN-MAULTSBY P et al: Rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. (1992) 43(3):779-784.
58. WATKINS SS, STINUS L, KOOB GF, MARKOU A: Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J. Pharmacol. Exp. Ther. (2000) 292(3):1053-1064.
59. SHAHAM Y, ADAMSON LK, GROCKI S, CORRIGALL WA: Reinstatement and spontaneous recovery of nicotine seeking in rats. Psychopharmacology (Berl.) (1997) 130(4):396-403.
60. LE FOLL B, GOLDBERG SR: Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl.) (2006) 184(3-4):367-381.
61. ROSE JE, CORRIGALL WA: Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology (Berl.) (1997) 130(1):28-40.
62. STOLERMAN IP: Inter-species consistency in the behavioural pharmacology of nicotine dependence. Behav. Pharmacol. (1999) 10(6-7):559-580.
63. 3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology (2003) 28(2):329-338.
64. 3R partial agonist BP 897 attenuates the discriminative stimulus effects of cocaine and amphetamine and is not self-administered. Behav. Pharmacol. (2001) 11:1-11.
65. 3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology (2003) 28(7):1272-1280.
66. 3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable- cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur. J. Neurosci. (2005) 21(12):3427-3438.
67. BICKEL WK, MARSCH LA, CARROLL ME: Deconstructing relative reinforcing efficacy and situating the measures of pharmacological reinforcement with behavioral economics: a theoretical proposal. Psychopharmacology (Berl.) (2000) 153(1):44-56.
68. DONNY EC, CAGGIULA AR, MIELKE MM et al.: Nicotine self-administration in rats on a progressive ratio schedule of reinforcement. Psychopharmacology (Berl.) (1999) 147(2):135-142.
69. B receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Pychopharmacology (Berl.) (2004) 172(2):179-186.
70. CAGGIULA AR, DONNY EC, CHAUDHRI N et al: Importance of nonpharmacological factors in nicotine self-administration. Physiol. Behav. (2002) 77(4-5):683-687.
71. LE FOLL B, GOLDBERG SR: Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol. Sci. (2005) 26(6):287-293.
72. DE WIT H, STEWART J: Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology (1981) 75:134-143.
73. STEWART J: Conditioned and unconditioned drug effects in relapse to opiate and stimulant drug-administration. Prog. Neuropsychopharmacol. Biol. Psychiatry (1983) 7:591-597.
74. ARROYO M, MARKOU A, ROBBINS TW, EVERITT BJ: Acquisition, maintenance and reinstatement of intravenous cocaine self-administration under a second-order schedule of reinforcement in rats: effects of conditioned cues and continuous acces to cocaine. Psychopharmacology (1999) 140:331-344.
75. 3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int. J. Neuropsychopharmacol. (2006) 9(5):585-602.
76. LE FOLL B, GOLDBERG SR: Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl.) (2005) 178:481-492.
77. FRACÈS H, LE FOLL B, DIAZ J, SMIRNOVA M, SOKOLOFF P: Role of DRD3 in morphine-induced conditioned place preference using DRD3-knockout mice. Neuroreport (2004) 15(14):2245-2249.
78. SHAHAM Y, SHALEV U, LU L, DE WIT H, STEWART J: The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl.) (2003) 168(1-2):3-20.
79. KATZ JL, HIGGINS ST: The validity of the reinstatement model of craving and relapse to drug use. Pychopharmacology (Berl.) (2003) 168(1-2):21-30.
80. 3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl.) (2004) 176(1):57-65.
81. ETTER JF: Cytisine for smoking cessation: a literature review and a meta-analysis. Arch. Intern. Med. (2006) 166(15):1553-1559.
82. HUGHES JR, STEAD LF, LANCASTER T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev. (2003) 2:CD000031.
83. HUGHES JR, HATSUKAMI DK, PICKENS RW et al.: Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berl.) (1984) 83(1):82-87.
84. WEST RJ, JARVIS MJ, RUSSELL MA, CARRUTHERS ME, FEYERABEND C: Effect of nicotine replacement on the cigarette withdrawal syndrome. Br. J. Addict. (1984) 79(2):215-219.
85. BRODY AL, MANDELKERN MA, LEE G et al.: Attenuation of cue-induced cigarette craving and anterior cingulace cortex activation in bupropion-treated smokers: a preliminary study. Pychiatry Res. (2004) 130(3):269-281.
86. HURT RD, SACHS DP, GLOVER ED et al.: A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl J. med. (1997) 337(17):1195-1202.
87. JORENBY DE, LEISCHOW SJ, NIDES MA et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med (1999) 340(9):685-691.
88. SHIFFMAN S, JOHNSTON JA, KHAYRALLAH M et al.: The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl.) (2000) 148(1):33-40.
89. SILAGY C, MANT D, FOWLER G, LANCASTER T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. (2000) 2:CD000146.
90. SILAGY C, LANCASTER T, STEAD L, MANT D, FOWLER G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. (2004) 3:CD000146.
91. LESAGE MG, KEYLER DE, SHOEMAN D et al.: Continuous nicotine infusion reduces nicotine self-administration in rats with 23-h/day access to nicotine. Pharmacol. Biochem. Behav. (2002) 72(1-2):279-289.
92. LESAGE MG, KEYLER DE, COLLINS G, PENTEL PR: Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations. Pychopharmacology (Berl.) (2003) 170(3):278-286.
93. COE JW, BROOKS PR, VETELINO MG et al: Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. (2005) 48(10):3474-3477.
94. COHEN C, BERGIS OE, GALLI F et al.: SSR591813, a novel selective and partial α4β2 nicotinic receptor agonist with potential as an aid to smoking cessation. J. Pharmacol. Exp. Ther. (2003) 306(1):407-420.
95. SANDS SB, BROOKS PR, CHAMBERS LK et al.: A new therapy for smoking cessation: varenicline, a selective nicotinic receptor partial agonist. SRNT's 11th Annual Meeting and 7th Annual European Conference, Prague, Czech Republic (2005).
96. WARNER C, SHOAIB M: How does bupropion work as a smoking cessation aid? Addict. Biol. (2005) 10(3):219-231.
97. YOUNG R, GLENNON RA: Nicotine and bupropion share a similar discriminative stimulus effect. Eur. J. Pharmacol. (2002) 443(1-3):113-118.
98. WILEY JL, LAVECCHIA KL, MARTIN BR, DAMAJ MI: Nicotine-like discriminative stimulus effects of bupropion in rats. Exp. Clin. Psychopharmacol. (2002) 10(2):129-135.
99. SHOAIB M, SIDHPURA N, SHAFAIT S: Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl.) (2003) 165(4):405-412.
100. CRYAN JF, BRUIJNZEEL AW, SKJEI KL, MARKOU A: Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl.) (2003) 168(3):347-358.
101. BRUIJNZEEL AW. MARKOU A: Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse (2003) 50(1):20-28.
102. RAUHUT AS, NEUGEBAUER N, DWOSKIN LP, BARDO MT. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berl.) (2003) 169(1):1-9.
103. COLPAERT FC: Drug discrimination in neurobiology. Pharmacol. Biochem. Behav. (1999) 64(2):337-345.
104. 1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport (2004) 15(13):2139-2143.
105. COOPER BR, HESTER TJ, MAXWELL RA: Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J. Pharmacol. Exp. Ther. (1980) 215(1):127-134.
106. PORSOLT RD, ANTON G, BLAVET N, JALFRE M: Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. (1978) 47:379-391.
107. RENARD CE, FIOCCO AJ, CLENET F, HASCOET M, BOURIN M: Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology (Berl.) (2001) 159(1):42-50.
108. 3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. (2000) 20(23):8677-8684.
109. 1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology (2002) 43(5):857-867.
110. 1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav. Brain Res. (2001) 118(1):61-65.
111. 1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Phamacol. (2002) 13(5-6):451-463.
112. 1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. Neuropsychopharmacology (2003)29(5):911-920.
113. 1 receptor antagonists for the treatment of nicotine addiction. Pharmacol. Biochem. Behav. (2005) 81(2):387-395.
114. CHAUDHRI N, CAGGIULA AR, DONNY EC et al.: Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology (Berl.) (2006) 184(3-4):353-366.
115. 3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats. Neuropsychopharmacology (2003) 28(11):1903-1915.
116. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. Current Drug Targets - CNS & Neurological Disorders (2006) 5(1):25-43.